Zoetis Inc. (NYSE:ZTS) Shares Sold by Private Advisor Group LLC

Private Advisor Group LLC lowered its position in Zoetis Inc. (NYSE:ZTS) by 3.6% during the third quarter, HoldingsChannel.com reports. The fund owned 28,495 shares of the company’s stock after selling 1,054 shares during the quarter. Private Advisor Group LLC’s holdings in Zoetis were worth $5,567,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of ZTS. Webster Bank N. A. grew its holdings in shares of Zoetis by 89.1% in the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after acquiring an additional 82 shares during the period. Quarry LP lifted its stake in Zoetis by 273.2% in the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after buying an additional 153 shares in the last quarter. LRI Investments LLC purchased a new stake in Zoetis in the 1st quarter valued at approximately $43,000. Central Valley Advisors LLC purchased a new stake in Zoetis in the 2nd quarter valued at approximately $49,000. Finally, EdgeRock Capital LLC purchased a new stake in Zoetis in the 2nd quarter valued at approximately $56,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

ZTS has been the topic of a number of recent research reports. Stifel Nicolaus upped their target price on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday, September 18th. Argus raised Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. BTIG Research increased their price target on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Piper Sandler increased their price target on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Finally, JPMorgan Chase & Co. increased their price target on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Zoetis presently has an average rating of “Buy” and a consensus target price of $221.44.

Zoetis Stock Performance

Shares of ZTS opened at $180.01 on Friday. The firm has a 50-day moving average price of $189.10 and a 200 day moving average price of $177.71. The firm has a market capitalization of $82.14 billion, a PE ratio of 34.68, a P/E/G ratio of 2.94 and a beta of 0.89. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $201.92.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The company had revenue of $2.36 billion during the quarter, compared to analyst estimates of $2.31 billion. During the same quarter last year, the firm posted $1.41 EPS. The business’s revenue for the quarter was up 8.3% on a year-over-year basis. On average, sell-side analysts anticipate that Zoetis Inc. will post 5.83 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be given a $0.432 dividend. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.96%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis’s dividend payout ratio (DPR) is 33.14%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.